RECURRENT PLASMA CELL MYELOMA

This early-phase study tests two drugs—venetoclax and tocilizumab—in people with a specific type of multiple myeloma (t(11;14)) that has returned or not responded to prior treatments. The goal is to find the safest dose and watch for side effects in both African American and non-…

This study is for people whose multiple myeloma has returned or stopped responding to at least three prior treatments. Researchers are testing whether adding a lab-modified virus (pelareorep) to a standard drug combination (bortezomib, dexamethasone, and pembrolizumab) can safely…

This study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…

This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells (T cells) that are specially trained to recognize and attack cancer cells carrying a protein called MUC…

This study tests a two-part treatment plan for people with multiple myeloma that has come back or is not responding to therapy. First, patients receive daratumumab, bortezomib, and dexamethasone, then switch to daratumumab, ixazomib, and dexamethasone. The goal is to see if this …

This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in adults with multiple myeloma that has come back or is not responding to prior treatments. The goal is to see if this mix can shrink or control the cancer. The trial enrolled 5 participant…

This study tracks how often cancer patients experience cachexia (unexplained weight loss and appetite loss) and measures the emotional burden on both patients and their primary caregivers. About 192 patients and their caregivers will fill out questionnaires at a supportive care c…